ADR of endoscopists inversely associated with the risk for interval postcolonoscopy CRC in FIT-positive individuals
TUESDAY, Sept. 27, 2022 (HealthDay News) — The adenoma detection rate (ADR) of endoscopists is associated with the risk for interval postcolonoscopy colorectal cancers (PCCRCs) after a positive fecal immunochemical testing (FIT) result, according to a study published online Sept. 27 in the Annals of Internal Medicine.
Pieter H.A. Wisse, M.D., from the Erasmus University Medical Center in Rotterdam, Netherlands, and colleagues examined the association between the ADR and PCCRC risk in colonoscopies performed after a positive FIT result in a population-based cohort study. PCCRCs were classified as interval, in which a cancer was detected before recommended surveillance, or noninterval.
A total of 362 endoscopists performed 116,360 colonoscopies, with a median ADR of 67 percent. The researchers identified 209 interval PCCRCs. The ADR was associated with interval PCCRC; for each 1 percent increase in ADR, there was an adjusted hazard ratio of 0.95. The expected number of interval PCCRC diagnoses after five years was about 2.0 per 1,000 patients undergoing colonoscopy for endoscopists with ADRs of 70 percent compared with more than 2.5, almost 3.5, and more than 4.5 for those with ADRs of 65, 60, and 55 percent, respectively.
“This supports the use of ADR as an important quality indicator for endoscopists performing colonoscopy in all CRC screening programs,” the authors write. “Based on the outcome of this study, the ADR target for endoscopists performing colonoscopy after a positive FIT result should be increased.”
Abstract/Full Text (subscription or payment may be required)
Surveillance Colonoscopy at Five Years After Adenoma Removal Noninferior to Three Years
Family History of CRC Increases CRC Risk Similarly in IBD, General Population
H. Pylori Exposure May Contribute to Global Burden of Colorectal Cancer
Lower Breast, Cervical Cancer Screening Seen for Adults With Disabilities
Mammography Trials Yield Excess-Incidence Patterns Consistent With Low Overdiagnosis
Alcohol-Attributable Cancer Mortality Has Increased Significantly in the U.S.
2005 to 2023 Saw More U.S. Women Never Screened for Cervical Cancer
Chemo-Free Combo of Four Targeted Therapies Shows Promise in Metastatic Breast Cancer